Literature DB >> 10340960

In situ zymographic localisation of type II collagen degrading activity in osteoarthritic human articular cartilage.

A J Freemont1, R J Byers, Y O Taiwo, J A Hoyland.   

Abstract

OBJECTIVES: Chondrocytic matrix metalloproteinases (MMPs) are believed to be important in osteoarthritic cartilage degradation. The cartilage lesion of osteoarthritis (OA) is focal and often progressive. During its development chondrocytes differentially up and down regulate production of mRNA for individual MMPs. This observation has potential implications for understanding the disease processes that lead to progressive cartilage loss in OA and designing appropriate targeted treatment. The complex regulation of MMP mediated effects means there is a pressing need to establish whether visualisation of MMP mRNA or protein equates to enzyme activity. The technique of in situ zymography (ISZ) offers a way of examining diseased human tissue for in vivo production of an excess of degrading enzyme over inhibitor. The primary objective of this study was to assess, and if positive follow, collagen II degrading activity in cartilage during development of the OA lesion. A secondary objective was to assess whether there was any correlation between sites of collagen II degrading activity and expression of the collagenase (MMP-13), recently implicated in type II collagen degredation in this lesion.
METHODS: Biopsied human normal and osteoarthritic cartilage, showing various degrees of damage, was examined by in situ zymography, with and without enzyme inhibitors, to establish sites of type II collagenase activity. Paired samples were probed for MMP-13 mRNA using 35S-labelled oligonucleotide probes. Comparative analyses were performed.
RESULTS: In situ zymography showed collagen II degrading activity over chondrocytes only in osteoarthritic cartilage. Distribution and amount varied with the extent of cartilage damage and position of chondrocytes, being greatest in deep cartilage and in cartilage lesions where fissuring was occurring. The enzyme causing the degradation behaved as a matrix metalloproteinase. MMP-13 mRNA expression codistributed with the type II collagenase activity.
CONCLUSION: In OA, chondrocytes can degrade type II collagen. The type II collagen degrading activity varies in site and amount as the cartilage lesion progresses and throughout codistributes with MMP-13 mRNA expression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10340960      PMCID: PMC1752894          DOI: 10.1136/ard.58.6.357

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  40 in total

1.  The proteoglycanase from human cartilage and cultured rabbit chondrocytes and its relation to osteoarthritis.

Authors:  S Sapolsky; C Malemud; M Sheff
Journal:  J Rheumatol       Date:  1987-05       Impact factor: 4.666

2.  Gene expression of matrix metalloproteinases 1, 3, and 9 by chondrocytes in osteoarthritic human knee articular cartilage is zone and grade specific.

Authors:  A J Freemont; V Hampson; R Tilman; P Goupille; Y Taiwo; J A Hoyland
Journal:  Ann Rheum Dis       Date:  1997-09       Impact factor: 19.103

3.  Collagenase-3 (MMP-13) is expressed during human fetal ossification and re-expressed in postnatal bone remodeling and in rheumatoid arthritis.

Authors:  M Ståhle-Bäckdahl; B Sandstedt; K Bruce; A Lindahl; M G Jiménez; J A Vega; C López-Otín
Journal:  Lab Invest       Date:  1997-05       Impact factor: 5.662

4.  Damage to type II collagen in aging and osteoarthritis starts at the articular surface, originates around chondrocytes, and extends into the cartilage with progressive degeneration.

Authors:  A P Hollander; I Pidoux; A Reiner; C Rorabeck; R Bourne; A R Poole
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

5.  Osteoarthritic lesions: involvement of three different collagenases.

Authors:  B V Shlopov; W R Lie; C L Mainardi; A A Cole; S Chubinskaya; K A Hasty
Journal:  Arthritis Rheum       Date:  1997-11

6.  Proteoglycans from experimental osteoarthritic cartilage: degradation by neutral metalloproteases.

Authors:  J P Pelletier; J Martel-Pelletier; C J Malemud
Journal:  J Rheumatol       Date:  1987-05       Impact factor: 4.666

7.  Biochemical characterization of human collagenase-3.

Authors:  V Knäuper; C López-Otin; B Smith; G Knight; G Murphy
Journal:  J Biol Chem       Date:  1996-01-19       Impact factor: 5.157

8.  Role of metalloproteinases in human osteoarthritis.

Authors:  J F Woessner; Z Gunja-Smith
Journal:  J Rheumatol Suppl       Date:  1991-02

Review 9.  Are cytokines involved in osteoarthritic pathophysiology?

Authors:  J P Pelletier; P J Roughley; J A DiBattista; R McCollum; J Martel-Pelletier
Journal:  Semin Arthritis Rheum       Date:  1991-06       Impact factor: 5.532

10.  Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis.

Authors:  J Martel-Pelletier; R McCollum; N Fujimoto; K Obata; J M Cloutier; J P Pelletier
Journal:  Lab Invest       Date:  1994-06       Impact factor: 5.662

View more
  8 in total

Review 1.  Cell and molecular biology of intervertebral disc degeneration: current understanding and implications for potential therapeutic strategies.

Authors:  S Z Wang; Y F Rui; J Lu; C Wang
Journal:  Cell Prolif       Date:  2014-08-11       Impact factor: 6.831

2.  Analysis of the trajectory of osteoarthritis development in a mouse model by serial near-infrared fluorescence imaging of matrix metalloproteinase activities.

Authors:  Averi A Leahy; Shadi A Esfahani; Andrea T Foote; Carrie K Hui; Roshni S Rainbow; Daisy S Nakamura; Brian H Tracey; Umar Mahmood; Li Zeng
Journal:  Arthritis Rheumatol       Date:  2015-02       Impact factor: 10.995

3.  Type II and VI collagen in nasal and articular cartilage and the effect of IL-1alpha on the distribution of these collagens.

Authors:  I D C Jansen; A P Hollander; D J Buttle; V Everts
Journal:  J Mol Histol       Date:  2010-03-06       Impact factor: 2.611

4.  Differential expression patterns of matrix metalloproteinases and their inhibitors during development of osteoarthritis in a transgenic mouse model.

Authors:  H J Salminen; A-M K Säämänen; M N Vankemmelbeke; P K Auho; M P Perälä; E I Vuorio
Journal:  Ann Rheum Dis       Date:  2002-07       Impact factor: 19.103

5.  Protective effects of total fraction of avocado/soybean unsaponifiables on the structural changes in experimental dog osteoarthritis: inhibition of nitric oxide synthase and matrix metalloproteinase-13.

Authors:  Christelle Boileau; Johanne Martel-Pelletier; Judith Caron; Philippe Msika; Georges B Guillou; Caroline Baudouin; Jean-Pierre Pelletier
Journal:  Arthritis Res Ther       Date:  2009-03-16       Impact factor: 5.156

6.  Interleukin-1 receptor antagonist delivered directly and by gene therapy inhibits matrix degradation in the intact degenerate human intervertebral disc: an in situ zymographic and gene therapy study.

Authors:  Christine L Le Maitre; Judith A Hoyland; Anthony J Freemont
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

7.  Effects of insulin-like growth factor-induced Wharton jelly mesenchymal stem cells toward chondrogenesis in an osteoarthritis model.

Authors:  Wahyu Widowati; Ervi Afifah; Tjandrawati Mozef; Ferry Sandra; Rizal Rizal; Annisa Amalia; Yukko Arinta; Indra Bachtiar; Harry Murti
Journal:  Iran J Basic Med Sci       Date:  2018-07       Impact factor: 2.699

8.  Chondroprotective Effects of a Histone Deacetylase Inhibitor, Panobinostat, on Pain Behavior and Cartilage Degradation in Anterior Cruciate Ligament Transection-Induced Experimental Osteoarthritic Rats.

Authors:  Zhi-Hong Wen; Jhy-Shrian Huang; Yen-You Lin; Zhi-Kang Yao; Yu-Cheng Lai; Wu-Fu Chen; Hsin-Tzu Liu; Sung-Chun Lin; Yu-Chi Tsai; Tsung-Chang Tsai; Yen-Hsuan Jean
Journal:  Int J Mol Sci       Date:  2021-07-07       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.